EUPRAXIA PHARMACEUTICALS INC (EPRX) Institutional Ownership Changes & 13F Activity
EUPRAXIA PHARMACEUTICALS INC (EPRX). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q2 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Ameriprise Financial Inc, Pfm Health Sciences, Lp, Millennium Management Llc, Ally Bridge Group (Ny) Llc, and Ikarian Capital, Llc.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| Citadel Advisors Llc | Buy | +271,835 | +118.1% | 502,011 | $3.32M | Q2 2026 | Sep 02, 2026 |
| Seven Fleet Capital Management Lp | Buy | +177,270 | +40.9% | 610,785 | $4.04M | Q2 2026 | Aug 17, 2026 |
| Stonepine Capital Management, Llc | Buy | +43,491 | — | 43,491 | $287.48K | Q2 2026 | Aug 17, 2026 |
| Ameriprise Financial Inc | Buy | +711,024 | — | 711,024 | $4.70M | Q2 2026 | Aug 14, 2026 |
| Pfm Health Sciences, Lp | Buy | +669,790 | +123.8% | 1,210,661 | $8.00M | Q2 2026 | Aug 14, 2026 |
| Millennium Management Llc | Buy | +441,586 | — | 441,586 | $2.92M | Q2 2026 | Aug 14, 2026 |
| Ally Bridge Group (Ny) Llc | Sell | -408,200 | -61.8% | 252,175 | $1.67M | Q2 2026 | Aug 14, 2026 |
| Ikarian Capital, Llc | Sell | -405,000 | -33.3% | 809,741 | $5.35M | Q2 2026 | Aug 14, 2026 |
| Woodline Partners Lp | Buy | +306,313 | +69.5% | 746,864 | $4.94M | Q2 2026 | Aug 14, 2026 |
| Jane Street Group, Llc | Buy | +293,843 | +834.5% | 329,053 | $2.16M | Q2 2026 | Aug 14, 2026 |
| Orbimed Advisors Llc | Buy | +269,000 | — | 269,000 | $1.78M | Q2 2026 | Aug 14, 2026 |
| Point72 Asset Management, L.P. | Sell | -237,291 | -24.5% | 730,284 | $4.83M | Q2 2026 | Aug 14, 2026 |
| Dafna Capital Management Llc | Buy | +225,600 | — | 225,600 | $1.49M | Q2 2026 | Aug 14, 2026 |
| Two Sigma Investments, Lp | Buy | +210,284 | +1947.1% | 221,084 | $1.46M | Q2 2026 | Aug 14, 2026 |
| Rubric Capital Management Lp | Buy | +176,254 | +25.5% | 867,424 | $5.73M | Q2 2026 | Aug 14, 2026 |
| Boothbay Fund Management, Llc | Sell | -111,190 | -34.3% | 212,653 | $1.41M | Q2 2026 | Aug 14, 2026 |
| Redmile Group, Llc | Sell | -88,600 | -12.7% | 611,400 | $4.04M | Q2 2026 | Aug 14, 2026 |
| Xtx Topco Ltd | Buy | +70,265 | — | 70,265 | $464.45K | Q2 2026 | Aug 14, 2026 |
| Royal Bank Of Canada | Buy | +50,059 | +19.2% | 311,435 | $2.06M | Q2 2026 | Aug 14, 2026 |
| Brevan Howard Capital Management Lp | Buy | +34,767 | — | 34,767 | $229.81K | Q2 2026 | Aug 14, 2026 |
| Qube Research & Technologies Ltd | Buy | +34,237 | — | 34,237 | $226.31K | Q2 2026 | Aug 14, 2026 |
| Shay Capital Llc | Buy | +10,000 | — | 10,000 | $66.10K | Q2 2026 | Aug 14, 2026 |
| Summittx Capital, L.P. | Sell | -9,213 | -2.8% | 318,784 | $2.11M | Q2 2026 | Aug 14, 2026 |
| Ingalls & Snyder Llc | Sell | -7,200 | -9.5% | 68,450 | $452.00K | Q2 2026 | Aug 14, 2026 |
| Goldman Sachs Group Inc | Buy | +4,978 | +9.4% | 58,058 | $383.76K | Q2 2026 | Aug 14, 2026 |
| Bank Of America Corp | Sell | -3,500 | -1.3% | 264,721 | $1.75M | Q2 2026 | Aug 14, 2026 |
| Raymond James Financial Inc | Buy | +2,943 | +5.8% | 53,503 | $353.65K | Q2 2026 | Aug 14, 2026 |
| Toronto Dominion Bank | Sell | -1,978 | -6.0% | 30,920 | $202.77K | Q2 2026 | Aug 14, 2026 |
| Quarry Lp | Buy | +49 | — | 49 | $324.00 | Q2 2026 | Aug 14, 2026 |
| Balyasny Asset Management L.P. | Buy | +15 | +0.0% | 1,350,015 | $8.92M | Q2 2026 | Aug 14, 2026 |
Frequently asked questions about EPRX activity
Which institutional owners are buying EPRX?
Institutional owners buying EPRX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in EPRX activity?
"Buy" means an investor increased their reported position in EPRX compared to the prior reporting period. This reflects growing exposure to EUPRAXIA PHARMACEUTICALS INC (EPRX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in EPRX increasing?
Institutional interest in EPRX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.